Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Rick Rieder, Chief Investment Officer at BlackRock, revealed in a recent interview with CNBC that the asset management giant has moderately reduced its holdings and rebalanced its portfolio in some companies that are directly related to artificial intelligence.

Rick Rieder, Chief Investment Officer at BlackRock, revealed in a recent interview with CNBC that the asset management giant has moderately reduced its holdings and rebalanced its portfolio in some companies that are directly related to artificial intelligence.

老虎证券老虎证券2026/07/08 19:28
Show original
Reid stated that although the long-term outlook for the artificial intelligence sector remains promising, the valuations of some related companies have risen sharply, prompting management teams to adopt more prudent portfolio adjustment strategies. This move reflects BlackRock’s investment philosophy of actively capturing technology growth opportunities while also placing emphasis on risk management and valuation discipline. He stressed that portfolio adjustments are an ongoing process aimed at optimizing risk-adjusted returns. This partial rebalancing of the artificial intelligence theme does not imply a bearish outlook for the sector, but is a tactical allocation optimization based on the current market environment.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11